Centocor serum tumor marker reclassification petition to go before FDA panel.
This article was originally published in The Gray Sheet
SERUM TUMOR MARKER DOWNCLASSIFICATION PETITION TO BE REVIEWED BY PANEL, FDA staffers say. The agency is planning a fall meeting of its Immunology Devices Panel to address a citizens petition recently submitted by Centocor seeking reclassification of serum tumor markers from their current Class III status to Class II. FDA had been planning a public workshop for this summer on the regulatory status of the devices; however, scheduling problems with possible participants and the submission of the Centocor petition convinced the agency that a panel meeting would be a more appropriate forum for discussion of the issue.
You may also be interested in...
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.